News
SLP
18.50
0.00%
0.00
BTIG Suspends Neutral Rating on Simulations Plus
Benzinga · 6d ago
*News On Simulations Plus Inc. (SLP) Now Under ALTA.XX
Dow Jones · 10/06 21:08
Simulations Plus Completes Altaris Acquisition and Goes Private
TipRanks · 10/06 20:53
Press Release: Simulations Plus Announces Completion of Acquisition by Altaris
Dow Jones · 10/06 13:15
Weekly Report: what happened at SLP last week (0928-1002)?
Weekly Report · 10/05 09:43
'HHS launches project to speed up clinical trials' - Axios
Benzinga · 09/30 19:17
Weekly Report: what happened at SLP last week (0921-0925)?
Weekly Report · 09/28 09:40
Weekly Report: what happened at SLP last week (0914-0918)?
Weekly Report · 09/21 09:40
Simulations Plus expands FDA partnership with ADMET predictor software deal
Seeking Alpha · 09/18 04:48
Simulations Plus expands FDA adoption of ADMET Predictor in cosmetic safety
TipRanks · 09/17 22:00
Simulations Plus Announces The FDA Cosmetics Regulatory Science Branch Has Licensed ADMET Predictor To Support Its Computational Research For Modern Cosmetic Safety Assessment
Benzinga · 09/17 21:50
Weekly Report: what happened at SLP last week (0907-0911)?
Weekly Report · 09/14 09:43
Weekly Report: what happened at SLP last week (0831-0904)?
Weekly Report · 09/07 09:40
Weekly Report: what happened at SLP last week (0824-0828)?
Weekly Report · 08/31 09:43
Simulations Plus Shareholders Approve Merger with Altaris Affiliate
TipRanks · 08/28 21:18
Weekly Report: what happened at SLP last week (0817-0821)?
Weekly Report · 08/24 09:44
Weekly Report: what happened at SLP last week (0810-0814)?
Weekly Report · 08/17 09:44
Simulations Plus Advances Toward Altaris Acquisition With HSR Clearance
TipRanks · 08/13 21:41
Simulations Plus Clears HSR Waiting Period For Altaris Acquisition, Closing Expected In H2 2026
Benzinga · 08/13 21:02
Press Release: Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris
Dow Jones · 08/13 21:00
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.